

**GENETICS,
CELL
DIFFERENTIATION,
AND CANCER**

Editor
PAUL A. MARKS

GENETICS, CELL DIFFERENTIATION, AND CANCER

Edited by

PAUL A. MARKS

DeWitt Wallace Research Laboratory

Sloan-Kettering Institute

Memorial Sloan-Kettering Cancer Center

New York, New York



1985

ACADEMIC PRESS, INC.

Harcourt Brace Jovanovich, Publishers

Orlando San Diego New York Austin

London Montreal Sydney Tokyo Toronto

COPYRIGHT © 1985 BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.

Orlando, Florida 32887

United Kingdom Edition published by
ACADEMIC PRESS INC. (LONDON) LTD.

24-28 Oval Road, London NW1 7DX

LIBRARY OF CONGRESS CATALOGING IN PUBLICATION DATA

Main entry under title:

Genetics, cell differentiation, and cancer.

(Bristol-Myers cancer symposia ; 7)

Proceedings of the Seventh Annual Symposium on Cancer Research, held at the Memorial Sloan-Kettering Cancer Center, in Oct. 1984, on the occasion of its centennial year celebration in 1984, sponsored by the Bristol-Myers Company.

Includes index.

1. Cancer—Genetic aspects—Congresses. 2. Cell transformation—Congresses. 3. Cell differentiation—Congresses. 4. Oncogenes—Congresses. 5. Gene expression—Congresses. I. Marks, Paul A. II. Bristol-Myers Symposium on Cancer Research (7th : 1984 : Memorial Sloan-Kettering Cancer Center) III. Memorial Sloan-Kettering Cancer Center. IV. Bristol-Myers Company. V. Series. [DNLM: 1. Cell Differentiation—congresses.

2. Gene Expression Regulation—congresses. 3. Oncogenes—congresses. 4. Oncogenic Viruses—genetics—congresses. 5. Neoplasms—familial & genetic—congresses.

W3 BR429 v.7 / QZ 202 G3317 1984]

RC268.4.G455 1985 616.99'4071 85-9027

ISBN 0-12-473060-4 (alk. paper)

PRINTED IN THE UNITED STATES OF AMERICA

GENETICS, CELL DIFFERENTIATION, AND CANCER

BRISTOL-MYERS CANCER SYMPOSIA

Series Editor

MAXWELL GORDON

*Science and Technology Group
Bristol-Myers Company*

1. Harris Busch, Stanley T. Crooke, and Yerach Daskal (Editors).
Effects of Drugs on the Cell Nucleus, 1979.
2. Alan C. Sartorelli, John S. Lazo, and Joseph R. Bertino (Editors).
Molecular Actions and Targets for Cancer Chemotherapeutic Agents, 1981.
3. Saul A. Rosenberg and Henry S. Kaplan (Editors).
Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment, 1982.
4. Albert H. Owens, Jr., Donald S. Coffey, and Stephen B. Baylin (Editors).
Tumor Cell Heterogeneity: Origins and Implications, 1982.
5. Janet D. Rowley and John E. Ulmann (Editors).
Chromosomes and Cancer: From Molecules to Man, 1983.
6. Umberto Veronesi and Gianni Bonadonna (Editors).
Clinical Trials in Cancer Medicine: Past Achievements and Future Prospects, 1985.
7. Paul A. Marks (Editor).
Genetics, Cell Differentiation, and Cancer, 1985.

Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

SAMIT ADHYA (15), Department of Molecular Biology and Virology,
Memorial Sloan-Kettering Institute for Cancer Research, New York,
New York 10021

BECKY ADKINS¹ (171), European Molecular Biology Laboratory, 6900
Heidelberg, Federal Republic of Germany

KAREN ARTZT (95), Memorial Sloan-Kettering Cancer Center, New
York, New York 10021

DOROTHEA BENNETT (95), Memorial Sloan-Kettering Cancer Center,
New York, New York 10021

HARTMUT BEUG (171), European Molecular Biology Laboratory,
6900 Heidelberg, Federal Republic of Germany

J. MICHAEL BISHOP (135), Department of Microbiology and
Immunology, and The George Williams Hooper Foundation,
University of California Medical Center, San Francisco, California
94143

J.-F. BRIAT (47), Department of Biochemistry, University of
California, Berkeley, California 94720

JAMES BROACH (153), Department of Molecular Biology, Princeton
University, Princeton, New Jersey 08540

MICHAEL J. CHAMBERLIN (47), Department of Biochemistry,
University of California, Berkeley, California 94720

D. F. CLAYTON (119), The Rockefeller University, New York, New
York 10021

¹Present address: Department of Pathology, Stanford University Medical Center,
Stanford, California 94305.

- B. CLURMAN (127), Molecular Biology and Virology Program of the Graduate School, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
- FREDERICK R. CROSS (143), The Rockefeller University, New York, New York 10021
- J. E. DARNELL, JR. (119), The Rockefeller University, New York, New York 10021
- RUSSELL L. DEDRICK (47), Department of Biochemistry, University of California, Berkeley, California 94720
- JEFFREY DREBIN (165), Department of Rheumatology, Tufts University School of Medicine, Boston, Massachusetts
- OTTAVIO FASANO (153), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724
- JEFFREY FIELD (15), Department of Molecular Biology and Virology, Memorial Sloan-Kettering Institute for Cancer Research, New York, New York 10021
- J. M. FRIEDMAN (119), The Rockefeller University, New York, New York 10021
- R. C. GALLO (183), Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20205
- ELLEN A. GARBER (143), The Rockefeller University, New York, New York 10021
- M. GOODENOW (127), Molecular Biology and Virology, Program of the Graduate School, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
- THOMAS GRAF (171), European Molecular Biology Laboratory, 6900 Heidelberg, Federal Republic of Germany
- MARK GREENE (165), Department of Rheumatology, Tufts University School of Medicine, Boston, Massachusetts
- RICHARD GRONOSTAJSKI² (15), Department of Molecular Biology and Virology, Memorial Sloan-Kettering Institute for Cancer Research, New York, New York 10021
- J. GROOPMAN (183), Hematology/Oncology Division, Deaconess Medicine, Boston, Massachusetts 02215
- RONALD A. GUGGENHEIMER (15), Department of Molecular Biology and Virology, Memorial Sloan-Kettering Institute for Cancer Research, New York, New York 10021

²Present address: Department of Medical Genetics, University of Toronto, Toronto, Ontario, Canada M5S 1A8.

- B. HAHN (183), Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20205
- HIDESABURO HANAFUSA (143), The Rockefeller University, New York, New York 10021
- TERUKO HANAFUSA (143), The Rockefeller University, New York, New York 10021
- MICHELLE HANNA (47), Department of Biochemistry, University of California, Berkeley, California 94720
- A. HAYDAY (127), Massachusetts Institute of Technology, Cambridge, Massachusetts 12139
- W. HAYWARD (127), Molecular Biology and Virology Program of the Graduate School, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
- JERARD HURWITZ (15), Department of Molecular Biology and Virology, Memorial Sloan-Kettering Institute for Cancer Research, New York, New York 10021
- HIDEO IBA³ (143), The Rockefeller University, New York, New York 10021
- TATSUO ISHIKAWA (153), Institute of Applied Microbiology, University of Tokyo, Tokyo 113, Japan
- PATRICIA KAHN (171), European Molecular Biology Laboratory, 6900 Heidelberg, Federal Republic of Germany
- CAROLINE M. KANE (47), Department of Biochemistry, University of California, Berkeley, California 94720
- TOHRU KATAOKA (153), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724
- MARK KENNY (15), Department of Molecular Biology and Virology, Memorial Sloan-Kettering Institute for Cancer Research, New York, New York 10021
- R. LESTRANGE (127), Molecular Biology and Virology, Program of the Graduate School, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
- ACHIM LEUTZ (171), European Molecular Biology Laboratory, 6900 Heidelberg, Federal Republic of Germany
- JUDITH LEVIN (47), Department of Biochemistry, University of California, Berkeley, California 94720

³Present address: Department of Biophysics and Biochemistry, Faculty of Science, The University of Tokyo, Tokyo 113, Japan.

- JEFF LINDENBAUM (15), Department of Molecular Biology and Virology, Memorial Sloan-Kettering Institute for Cancer Research, New York, New York 10021
- P. D. MARKHAM (183), Department of Cell Biology, Litton Bionetics, Inc., Kensington, Maryland 20895
- PAUL A. MARKS (1, 105), DeWitt Wallace Research Laboratory, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021
- KUNIHITO MATSUMOTO⁴ (153), Department of Industrial Chemistry, Tottori University, Tottori 680, Japan
- KYOUSUKE NAGATA⁵ (15), Department of Molecular Biology and Virology, Memorial Sloan-Kettering Institute for Cancer Research, New York, New York 10021
- HOWARD A. NASH (75), Laboratory of Molecular Biology, National Institute of Mental Health, Bethesda, Maryland 20205
- DAVID PELLMAN (143), The Rockefeller University, New York, New York 10021
- M. POPOVIC (183), Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20205
- D. J. POWELL (119), The Rockefeller University, New York, New York 10021
- SCOTT POWERS (153), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724
- L. RATNER⁶ (183), Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20205
- M. REITZ (183), Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20205
- REBECCA REYNOLDS (47), Department of Biochemistry, University of California, Berkeley, California 94720
- ALEXANDER RICH (25), Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
- R. A. RIFKIND (105), DeWitt Wallace Research Laboratory, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

⁴Present address: DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, California 94304.

⁵Present address: Department of Molecular Genetics, National Institute of Genetics, Mishima, Shizuoka, Japan.

⁶Present address: Division of Hematology and Oncology, Washington University, St. Louis, Missouri.

- M. ROBERT-GUROFF (183), Laboratory of Tumor Cell Biology,
National Cancer Institute, Bethesda, Maryland 20205
- B. SAFAI (183), Memorial Sloan-Kettering Institute, New York, New
York 10021
- S. Z. SALAHUDDIN (183), Laboratory of Tumor Cell Biology,
National Cancer Institute, Bethesda, Maryland 20205
- M. G. SARNGADHARAN (183), Laboratory of Tumor Cell Biology,
National Cancer Institute, Bethesda, Maryland 20205
- ALAN SCHECHTER (165), Whitehead Institute for Biomedical
Research, Massachusetts Institute of Technology, Cambridge,
Massachusetts 02142
- MARTIN SCHMIDT (47), Department of Biochemistry, University of
California, Berkeley, California 94720
- G. SHAW⁷ (183), Laboratory of Tumor Cell Biology, National Cancer
Institute, Bethesda, Maryland 20205
- M. SHEFFERY (105), DeWitt Wallace Research Laboratory, Sloan-
Kettering Institute, Memorial Sloan-Kettering Cancer Center, New
York, New York 10021
- C.-K. SHIH (127), Molecular Biology and Virology Program of the
Graduate School, Memorial Sloan-Kettering Cancer Center, New
York, New York 10021
- HEE-SUP SHIN (95), Memorial Sloan-Kettering Cancer Center, New
York, New York 10021
- M. SIMON (127), Molecular Biology and Virology, Program of the
Graduate School, Memorial Sloan-Kettering Cancer Center, and
The Rockefeller University, New York, New York 10021
- DAVID F. STERN (165), Whitehead Institute for Biomedical Research,
Massachusetts Institute of Technology, Cambridge, Massachusetts
02142
- TATSUO TAKEYA⁸ (143), The Rockefeller University, New York, New
York 10021
- TAKASHI TODA (153), Cold Spring Harbor Laboratory, Cold Spring
Harbor, New York 11724
- S. TONEGAWA (127), Massachusetts Institute of Technology,
Cambridge, Massachusetts 02139

⁷Present address: Division of Hematology and Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama.

⁸Present address: Institute for Chemical Research, Kyoto University, Kyoto-Fu 611, Japan.

ISAO UNO (153), Institute of Applied Microbiology, University of Tokyo, Tokyo 113, Japan

LALITHA VAIDYANATHAN (165), Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142

ROBERT WEINBERG (165), Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142

MICHAEL WIGLER (153), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724

K. WIMAN (127), Molecular Biology and Virology Program of the Graduate School, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

F. WONG-STAAAL (183), Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, Maryland 20205

Editor's Foreword

This volume reports the proceedings of the seventh Bristol-Myers Symposium on Cancer Research. The third and sixth symposia (from Stanford and Milan, respectively) were primarily oriented toward clinical treatment. The first, second, fourth, and fifth volumes described basic subjects like effects of drugs on the cell nucleus (Baylor), molecular targets for drug action (Yale), tumor cell heterogeneity (Hopkins), and chromosomes as they relate to cancer (Chicago).

The title of this symposium at the Memorial Sloan-Kettering Cancer Center is "Genetics, Cell Differentiation, and Cancer." Thus, it covers many topics introduced at the University of Chicago symposium held in 1982. It is extraordinary to reflect how much basic research has accumulated in the intervening two years, an indication of the accelerating pace of basic research in cancer.

Among many other themes, the current volume highlights the importance of protein factors in the growth, differentiation, and control of cells. It is singularly apt that tumor necrosis factor, first characterized at the Memorial Sloan-Kettering Cancer Center a dozen years ago, has now been cloned by a number of laboratories around the world and is entering clinical trial. The finding at Sloan-Kettering and elsewhere, that γ interferon is highly synergistic with TNF, suggests avenues for clinical exploration. Finally, it is not far-fetched to speculate that as many as a half dozen lymphokines might be used together in patient treatment, involving such diverse elements as interleukin II, tumor inhibitor factor, transforming growth factor, lymphotoxin, etc.

Maxwell Gordon
Series Editor

Foreword

A century ago, the public's perception of cancer was still medieval; it was considered a disease of shame. When we think of impressive advances in prevention and treatment during the past few decades, we must also be thankful for the changes in public perception and acceptance that now permit us to discuss cancer with relative freedom and candor.

The intense public interest in news about all aspects of cancer research extends to basic science as well as to clinical applications. In recent years, the public has learned of stunning advances in the understanding of how normal cells grow and develop and of what happens when the controls to that growth and development break down. Never before in the history of molecular biology have there been so many ideas to be tested. Never before have there been so many techniques to evaluate them.

But there is another perspective as well. In the weeks just before this symposium was held, the British scientific journal *Nature* reversed its earlier editorial position, saying it had been "overly optimistic" in predicting the speed with which oncogene research would lead to an understanding of the cause of some forms of cancer. And it is indeed the case that although remarkable progress has been made in some areas, the problem of solving the cancer riddle remains a vast one.

It was to these unsolved problems that the distinguished scientists participating in the seventh annual Bristol-Myers Symposium on Cancer Research addressed themselves. The symposium series is an integral part of the \$8.34 million, no-strings-attached program of unrestricted grants for cancer research our company has sponsored since 1977 at 17 institutions in the United States and abroad.

The symposium organized by Memorial Sloan-Kettering Cancer Center had special meaning to us because it took place during Memorial Sloan-Kettering's centennial year and was held in New York, the city that has been our

company's corporate headquarters for more than 80 years. With the publication of these proceedings, we are pleased that the important insights shared with the investigators attending the 1984 symposium can now be shared with a broader audience.

Richard L. Gelb
Chairman of the Board
Bristol-Myers Company

Preface

The Memorial Sloan-Kettering Cancer Center celebrated its Centennial Year in 1984. As the major scientific meeting in this hundredth year, the symposium "Genetics, Cell Differentiation, and Cancer," the seventh annual symposium on cancer research, was organized by the Center and sponsored by the Bristol-Myers Company. This volume is composed of papers delivered by scientists who participated in this conference.

Remarkable progress has been made in our understanding of the nature of carcinogenesis and, in particular, of the role of protooncogenes and oncogenes in the transformation of normal to abnormal cells. As these proceedings demonstrate, work in several areas, including studies on DNA replication, protein synthesis, embryologic development, DNA and RNA viruses, growth factors, and receptors, are coming together to provide us with an understanding of the process of transformation on a molecular and cellular level. This volume provides elegant testimony to the importance of studies on prokaryotes, simple eukaryotic organisms such as yeast, and *Drosophila* in providing insight into the nature of cancer. The first series of papers in these proceedings reports on studies of DNA replication, DNA structure, RNA synthesis, and control of gene expression. Subsequent papers review recent research on oncogenes and their role in inducing malignant growth.

The organizing committee for this symposium comprised Drs. Dorothea Bennett, Bayard D. Clarkson, William Hayward, Samuel Hellman, Paul A. Marks, Malcolm Moore, Lloyd J. Old, and Richard A. Rifkind. We are grateful to all of the participants who made this symposium and this volume which records its proceedings such a memorable scientific event.

We are particularly appreciative of the support of Mr. Richard Gelb, Chairman of the Board of the Bristol-Myers Company and his colleagues, in particular Mr. Harry Levine, Ms. Ann Wyant, and Ms. Kathryn Bloom.

Ms. Suzanne Rauffenbart and Ms. Suzanne Emery of the Memorial Sloan-Kettering Cancer Center provided excellent staff work in all details related to the organization of the symposium. We also thank Ms. Helene Friedman for her expert assistance in the preparation of these proceedings.

Paul A. Marks

Abbreviations

abl, Abelson murine leukemia virus (mouse)

ad, adenovirus

AIDS, acquired immunodeficiency disease syndrome

ALL, acute lymphoblastic leukemia

AML, acute myelogenous leukemia

ALV, avian leukosis virus

ARC, AIDS-related complex

ATTB, bacterial attachment site

ATL, adult T-cell leukemia

att, attachment site

ATP, adenosine triphosphate

attP, phage attachment site

BCGF, B-cell growth factor

bg/l, restriction enzyme

BLV, bovine leukemia virus

c, cellular

CAT, chloramphenicol acetyl transferase

CFUe, colony-forming unit for erythropoiesis

CMGF, cellular myeloid growth factor

CML, chronic myelogenous leukemia

CMP, cytidine monophosphate

c-onc, cellular or protooncogenes

CSA, colony-stimulating factor

CTP, cytidine triphosphate

d, deoxy

DBP, DNA binding protein